Dysregulation of Autonomic Nervous System in Chagas’ Heart Disease Is Associated with Altered Adipocytokines Levels

João Marcos Barbosa-Ferreira¹*, Charles Mady¹, Barbara Maria Ianni¹, Heno Ferreira Lopes²,³, Felix José Alvarez Ramires¹, Vera Maria Cury Salemi¹, Cesar José Grupi⁴, Denise Tessariol Hachul⁵, Fábio Fernandes¹

¹ Cardiomyopathy Unit of the Heart Institute (InCor), do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ² Hypertension Unit of the Heart Institute (InCor), do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ³ Universidade Nove de Julho—UNINOVE, São Paulo, Brazil, ⁴ Electrocardiology Unit of the Heart Institute (InCor), do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ⁵ Clinical Arrhythmia Unit of the Heart Institute (InCor), do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil

* jmbemfica@hotmail.com

Abstract

Background

Chagas disease (CD) induces autonomic dysfunction and inflammatory activity, which may promote metabolic abnormalities. We studied metabolism and its correlation with Autonomic Nervous System (ANS) and inflammation in CD.

Methods and Results

Sixty subjects were divided into 4 groups: control group (CG), IF (indeterminate form) group; ECG group (ECG abnormalities and normal left ventricular systolic function), and LVD group (left ventricular systolic dysfunction). Levels of adiponectin, leptin, insulin, interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-alpha) were assayed in serum samples by ELISA. ANS was assessed by heart rate variability in frequency domain in 24-hour Holter and postural tilt test (rest and orthostatic position). High frequency (HFr) component values were used to estimate parasympathetic activity and low frequency (LFr) component, sympathetic activity. Analyzes were made of the correlations of each of the metabolic parameters (leptin and adiponectin) with the inflammatory cytokines (interleukin-6 and TNF- alpha) and with the ANS assessment measurements. No significant differences were observed in leptin and insulin levels. Adiponectin was higher in ECG and LVD group: [CG = 4766.5 (5529.5), IF = 4003.5 (2482.5), ECG = 8376.5 (8388.5), LVD = 8798 (4188.0) ng/mL, p<0.001]). IL-6 and TNF-alpha were higher in LVD group: [IL-6: CG = 1.85 (6.41); IF = 1.58 (1.91); ECG = 1.0 (1.57); LVD = 31.44 (72.19) pg/ml; p = 0.001. TNF-alpha: CG = 22.57 (88.2); IF = 19.31 (33.16); ECG = 12.45 (3.07); LVD = 75.15 (278.57) pg/ml; p = 0.04]. Adiponectin levels had a positive association with the HFr component (r = 0.539; p = 0.038).
and an inverse association with the LFr component ($r = -0.539; p = 0.038$) in ECG group. Leptin levels had a negative association with the HFr component ($r = -0.632; p = 0.011$) and a positive association with the LFr component ($r = 0.632; p = 0.011$) in LVD group.

**Conclusions**

We found increased adiponectin levels in Chagas’ heart disease with systolic dysfunction and in patients with ECG abnormalities and normal systolic function at rest. Adipocytokines levels (adiponectin and leptin) were associated with ANS parameters in Chagas’ heart disease.

**Introduction**

Chagas’ disease (CD) occurs from the southern United States to Patagonia and affects around 8 million people in Latin America [1]. Moreover, due to the intensification of the migratory flow, CD is becoming more relevant in nonendemic countries, such as the United States, Canada, some European countries, Japan, and Australia. In the United States, it is estimated that 300 thousand legal immigrants may be infected with the disease. Spain has the second largest prevalence with around 40 to 60 thousand infected immigrants [2]. The natural history of Chagas’ disease is summarized in the acute and chronic phases [3]. In the chronic phase, about 70% of the patients have no symptoms and routine examinations do not show any abnormalities. This stage is called indeterminate form (IF). The patients of IF form of Chagas’ disease, in general, have a very good prognosis. Survival in this group appears comparable to that of the general population [4]. The remaining 30% have the chronic digestive and/or cardiac form, and 10% of these patients may progress to severe forms of heart disease. The progression to myocardial dysfunction represents the leading cause of morbidity and mortality in Chagas’ disease [3]. Therefore, investigations regarding the pathophysiology of the development and progression of cardiomyopathy are of fundamental importance in the proposed new therapies in an attempt to minimize morbidity and mortality.

Myocardial damage directly related to parasite persistence, immunologic mechanisms, microvascular disturbances, and autonomic dysfunction are involved in the pathophysiological mechanism of chagasic cardiomyopathy [5]. Cardiac dysautonomia is a well-established feature of Chagas disease, in which anatomic denervation and functional abnormalities have been extensively described. Neuronal depopulation occurs in cardiac parasympathetic ganglia in Chagas’ heart disease associated with scattered sympathetic denervation [6]. Several methods are currently available to evaluate autonomic function such as Valsalva maneuver, deep breathing, orthostatic test and heart rate variability in the time domain or in the frequency domain [5]. Previous studies suggest that autonomic dysfunction may precede left ventricular systolic dysfunction [7,8]. The mechanisms of Chagas’ cardiomyopathy can influence other pathophysiological pathways, such as metabolic impairment.

Recent research has led to a growing appreciation of the complexity of metabolic aspects of heart failure (HF) pathophysiology. Not only the myocardium, but also peripheral tissues and organs are affected by metabolic failure, resulting in a global imbalance between catabolic and anabolic signals. Metabolic feedback signals from muscle and fat actively contribute to disease progression [9]. The adipocytokines are bioactive mediators produced by adipose tissue. The main adipocytokines are adiponectin and leptin. Adiponectin has beneficial anti-inflammatory and anti-atherogenic effects as well as insulin-sensitizing action [10–14]. However, the role of
Adiponectin in cardiovascular disease is still a controversy. Previous studies have demonstrated that adiponectin is increased in systolic HF patients, even predicting morbidity and mortality [15,16]. Leptin promotes pro-inflammatory and pro-thrombotic activities, neointimal proliferation, endothelial dysfunction and induction of insulin resistance [17,18]. In CD patients, we have previously found reduced leptin levels in Chagas' cardiomyopathy when compared with a control group and other forms of CD [19]. Our speculation is that chagasic patients have altered sympathetic activity resulting in decreased leptin synthesis.

So, the basic hypothesis is that chronic Chagas’ cardiomyopathy may serve as a model in which severe inflammatory activity and early involvement of the autonomic nervous system (ANS) influence metabolism. Alterations in metabolism such as insulin resistance and the role of adipose tissue can lead to a systemic inflammatory state that contributes to vasculopathy and cardiovascular risk [14]. This two-way mechanism can bring chronic metabolic complications of HF to the fore and gradually shift its clinical presentation. The study of this association can promote emerging therapeutic concepts with specific metabolic targets. The aim of this study was to evaluate the metabolic parameters in the different forms of Chagas’ disease and its association with inflammatory activity and with measures of autonomic nervous system function.

Materials and Methods

Patient selection

Sixty subjects were divided into 4 groups: control group (CG), IF (indeterminate form) group of Chagas disease; ECG group (Chagas heart disease with ECG abnormalities and normal left ventricular systolic function), and LVD group (Chagas heart disease with left ventricular systolic dysfunction). The control group consisted of 15 healthy individuals. IF group comprised subjects with 2 positive serologic reactions for Chagas’ disease and no cardiac involvement as defined by chest X-rays, 12-lead ECG, and 2-dimensional echocardiography. All patients had normal barium studies of the esophagus and the colon. ECG group consisted of patients with normal left ventricular (LV) systolic function showing right or left bundle-branch block, left anterior fascicular block, diffuse ST changes, ventricular premature beats that may be multiformal or runs of non-sustained ventricular tachycardia registered on the ECG. LVD group, comprised patients with LV dysfunction demonstrated by a left ventricular ejection fraction less than 40% in echocardiography. All of these groups were matched according to sex, age (± 2 years intervals), and body mass index (± 1 kg/m² intervals). The inclusion criteria were patients with 2 positive serologic reactions for Chagas’ disease and age over 18 years. The exclusion criteria were myocardial infarction (evaluated by Q waves on an electrocardiogram (ECG) or segmental left ventricular (LV) dysfunction by 2-dimensional echocardiography), moderate or severe valvar heart disease (evaluated by clinical examination and by Doppler echocardiography), arterial hypertension, smoking, diabetes mellitus, current use of statins, atrial fibrillation, advanced atrioventricular block, pacemaker, thyroid diseases, chronic obstructive pulmonary disease, and heart failure functional classes III and IV by the New York Heart Association (NYHA) classification. All subjects signed a written consent form, and the Ethics Committee of the Heart Institute (InCor), University of São Paulo Medical School approved the study.

Antropometric measurements

All subjects underwent anthropometric measurements such as weight, height, body mass index, and waist circumference. Bioelectrical impedance (BIA 450, Byodinamics, Seattle, USA) was used to assess percentage of body fat and fat mass.
Echocardiographic study

Comprehensive transthoracic echocardiographic studies were performed with a Sequoia 512 ultrasound machine (Acuson, Mountain View, CA USA). Two-dimensional guided M-mode measurements of the left ventricle (LV) in short axis view and LV, left atrium and right atrium end diastolic and end systolic volumes were taken from apical 4-chamber view. LV ejection fraction (LVEF) was calculated using a modified Simpson biplane method. LV regional wall motion was evaluated based on 17-segment model segmentation, and each segment was confirmed in multiple views as follows: normal or hyperkinesis, hypokinesis, akinesis, dyskinesis, and aneurysmal. Diastolic function was assessed from pulsed-wave Doppler of the transmitial inflow velocities, with the sample volume at the mitral valve leaflet tips, and from tissue Doppler imaging of the septal and lateral mitral annulus, both at apical 4-chamber view. Mitral, tricuspid, aortic, and pulmonary regurgitations were qualitatively evaluated.

Laboratory measurements

Fasting glucose, total cholesterol, HDL-cholesterol, LDL-cholesterol and tryglicerides were measured using standard assays.

The subjects underwent serum adiponectin, insulin, leptin, interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-alpha) measurements by ELISA. Serum insulin was measured with a commercially available kit (Millipore, St. Charles, Missouri, USA). The sensitivity of the kit was 1 μU/mL, and the reference interval was from 31 to 65 μU/ml. The measurements were made in duplicate with a coefficient of variation of 4.3%. Serum leptin was measured with a commercially available kit (Millipore, St. Charles, Missouri, USA). The sensitivity of the kit was 0.78 ng/mL, and the reference interval was from 12.9 to 26.8 ng/mL. The measurements were made in duplicate with a coefficient of variation of 7.3%. Serum adiponectin levels were measured with a commercially available kit (Millipore, St. Charles, Missouri, USA). The sensitivity of the kit was 100 ng/mL, and the reference interval was from 7000 to 14,500 ng/mL. The measurements were made in duplicate with a coefficient of variation of 3.1%. Interleukin-6 was measured with a commercially available kit (USCNK, Life Science Inc., Wuhan, China). The sensitivity of the kit was 5.6 pg/mL, and the reference interval was from 75 to 175 pg/mL. The measurements were made in duplicate with a coefficient of variation of 10.3%. Tumor necrosis factor-alpha was measured with a commercially available kit (USCNK, Life Science Inc., Wuhan, China). The sensitivity of the kit was 5.9 ng/mL, and the reference interval was from 150 to 175 pg/mL. The measurements were made in duplicate with a coefficient of variation of 6.4%.

Evaluation of autonomic nervous system function

The autonomic nervous system (ANS) function was evaluated by heart rate variability (HRV) in the frequency domain using Fast Fourier Transform model in 24-hour Holter and postural tilt test (rest and orthostatic position). The following indices were calculated: Total power, Low frequency (LFr) component in absolute values of power (ms²) and in normalized units (n.u.), High frequency (HFr) component in absolute values of power (ms²) and in normalized units (n.u.), and the LFr/HFr ratio. We also calculated the changes in LFr and HFr components from rest to orthostatic position. The increase of the LF component and the LFr/HFr ratio were interpreted as a predominance of sympathetic activity. The increase in the HFr component and the reduction in the LFr/HFr ratio were interpreted as a predominance of parasympathetic activity[20].

The following formula was used for the calculation of the LFr and HFr components in normalized units (n.u.):
- Component LFr or HFr in absolute values / (total power–very low frequency component) x 100

The patients were instructed not to take any stimulants, such as coffee, tea, soft drinks and alcoholic beverages, on the day prior to and on the day of the exams.

The “Task Force Monitor” (CNSystems Medizintechnik GmbH, Graz, Austria) was used for analysis during postural tilt testing. The five minutes immediately prior (rest in supine position) and the five minutes immediately after inclination (orthostatic position) were assessed. The mean of the spectral components obtained in the established times was calculated. Cardiac cycles with a variation greater than 25% to a previous one were excluded as a way of abolishing the consequent alterations to the ventricular and supraventricular extrasystoles. Only the readings with at least 85% sinus beats were assessed.

Statistical analyses
Statistical analyses were performed using ANOVA test to evaluate differences in means among groups. If the homogeneity of the variances was not observed, the non-parametric Kruskal-Wallis test was used. When there is evidence of difference in at least one group, it was used Tukey tests for comparisons. Spearman coefficient was used for correlation analysis. We evaluated the correlations in each of the three groups of patients with Chagas disease separately (IF group, ECG group and LVD group). The correlations were made between each of the adipocytokines (adiponectin and leptin) with the inflammatory cytokines (interleukin-6 and TNF-α) and with the ANS assessment measurements (in normalized units). A P value < 0.05 was considered statistically significant.

Results
Clinical characteristics
There were no significant differences in age, weight, and body mass index among groups. The ejection fraction was significantly lower in LVD group. Systolic and diastolic blood pressure was lower in the LVD group compared to other three groups. The fat mass was lower in the LVD group, with statistical significance for the absolute values. The drugs used by the individuals of the LVD group were as follows: amiodarone in three patients (20%), beta-blockers in 15 patients (100%), angiotensin converting enzyme inhibitors in 13 patients (86.6%), angiotensin receptor blockers in two patients (13.3%), furosemide in nine patients (60%), spironolactone in 11 patients (73.3%) and digoxin in one patient (6.6%). Individuals from others groups did not use any drugs. Baseline physical and hemodynamic characteristics in Chagas’ disease patients and healthy controls are displayed in Table 1.

Laboratory measurements
There were no significant differences in fasting glucose, total cholesterol, HDL-cholesterol, LDL-cholesterol, tryglicerides, leptin, and insulin among groups. Adiponectin was significantly increased in ECG and LVD groups compared to IF and control groups (p<0.001). The levels of interleukin-6 (p = 0.001) and tumor necrosis factor-alpha (p = 0.04) were higher in the LVD group compared to the other three groups. The data from metabolic and inflammatory parameters are described in Table 2.

Evaluation of autonomic nervous system function
The results of ANS study suggest a greater impairment of sympathetic branch in LVD group and a balanced impairment of parasympathetic and sympathetic branches in IF group and in
ECG group. The data related to the 24-hour Holter and postural tilt test in supine (rest) and in orthostatic position are detailed in Tables 3, 4 and 5.

Correlations

There were significant correlations between adiponectin with some ANS assessment indexes in ECG group. Adiponectin level is associated negatively with the LFr component and positively with the HFr component in 24-hour Holter. No correlations between adiponectin and inflammatory cytokines were found. The values of correlations of adiponectin are shown in Table 6.

Table 1. Clinical and hemodynamic characteristics of the studied population.

| Variable     | Control Group | IF Group | ECG Group | LVD Group | p value * |
|--------------|---------------|----------|-----------|-----------|-----------|
| Age (years)  | 43.8 (± 7.43) | 42.33 (± 7.30) | 43.20 (± 6.14) | 42.67 (± 6.72) | 0.942     |
| NYHA (I/II)  | -             | -        | -         | 4/11      | -         |
| HR (bpm)     | 74.93 (± 7.00) | 73.47 (± 9.20) | 73.33 (± 8.20) | 69.47 (± 10.91) | 0.604     |
| SBP (mmHg)   | 122.67 (± 7.04) | 120.67 (± 9.61) | 121.33 (± 9.90) | 101.33 (± 9.90)** | <0.001    |
| DBP (mmHg)   | 70.00 (± 7.56) | 72.67 (± 7.99) | 74.00 (± 7.37) | 62.67 (± 5.94) | 0.001     |
| BMI (kg/m²)  | 23.9 (± 1.20) | 23.9 (± 1.39) | 23.7 (± 1.20) | 23.2 (± 1.50) | 0.602     |
| Weight (kg)  | 70.4 (± 8.50) | 68.1 (± 10.00) | 67.8 (± 8.50) | 65.8 (± 8.80) | 0.595     |
| Fat mass (kg)| 15.7 (± 4.40) | 14.5 (± 5.80) | 14.3 (± 6.20) | 10.5 (± 3.30)** | 0.015     |
| Fat mass (%) | 22.9 (± 5.50) | 20.7 (± 8.10) | 21.4 (± 9.20) | 16.1 (± 5.00) | 0.071     |
| LVEF (%)     | 74.67 (± 4.61) | 74.87 (± 6.02) | 69.40 (± 8.97) | 30.20 (± 5.76)** | 0.049     |

Values expressed as mean (± SD)
* p values were calculated using ANOVA
** p<0.001 compared to control group using Tukey test
NYHA: New York Heart Association functional class; HR: heart rate; SBP: systolic blood pressure; DBP: diastolic blood pressure, BMI: body mass index; LVEF: left ventricular ejection fraction; kg: kilograms, %: percentage
doi:10.1371/journal.pone.0131447.t001

Table 2. Metabolic and inflammatory parameters.

| Variable           | Control Group | IF Group | ECG Group | LVD Group | p value * |
|--------------------|---------------|----------|-----------|-----------|-----------|
| Insulin (μU/mL)    | 3.41 (1.98)   | 4.31 (2.85) | 4.3 (3.06) | 4.58 (2.88) | 0.901     |
| Leptin (ng/mL)     | 3.42 (7.43)   | 3.03 (6.53) | 5.56 (6.20) | 2.86 (2.67) | 0.626     |
| Adiponectin (ng/mL)| 4766.5 (5529.50) | 4003.5 (2482.50) | 8376.5 (8388.50)** | 8798.0 (4188.00)** | <0.001    |
| Interleukin-6 (pg/mL) | 1.85 (6.41) | 1.58 (1.91) | 1.00 (1.57) | 31.44 (72.19)** | 0.001     |
| TNF-alpha (pg/mL)  | 22.57 (88.20) | 19.31 (33.16) | 12.45 (3.07) | 75.15 (278.57)** | 0.040     |
| Fasting glucose (mg/dL) | 93.47 (± 14.41) | 91.07 (± 9.04) | 93.80 (± 6.07) | 93.80 (± 8.18) | 0.589     |
| Total cholesterol (mg/dL) | 190.00 (± 28.03) | 186.10 (± 46.83) | 190.60 (± 31.09) | 193.70 (± 38.85) | 0.956     |
| LDL-cholesterol (mg/dL) | 116.60 (± 25.14) | 114.20 (± 42.00) | 119.80 (± 25.03) | 123.10 (± 34.38) | 0.689     |
| HDL-cholesterol (mg/dL) | 53.07 (± 17.05) | 48.47 (± 1.84) | 45.67 (± 8.76) | 49.53 (± 9.30) | 0.571     |
| Tryglicerides (mg/dL) | 101.30 (± 69.56) | 112.4 (± 63.61) | 125.8 (± 68.89) | 105.3 (± 81.80) | 0.395     |

Values expressed as medians (interquartile range))
* p values were calculated using Kruskal-Wallis test
** p<0.05 compared to the control group using Tukey test
TNF-alpha: tumor necrosis factor alpha
doi:10.1371/journal.pone.0131447.t002
Discussion

We found increased adiponectin levels in patients with Chagas’ heart disease. Furthermore, we observed a relationship in regard to adipocytokine levels and ANS function in Chagas’ heart disease. The levels of adiponectin are associated with reduced sympathetic activity and increased parasympathetic activity and the levels of leptin are associated with increased sympathetic activity and reduced parasympathetic activity in subjects with Chagas’ disease and cardiac involvement.

The levels of adiponectin have already been evaluated in animal models of acute infection with *Trypanosoma cruzi*. In 2005, Coombs et al conducted a study of infected rats during the acute phase of Chagas’ disease, demonstrating that the adipocytes infected with *T. cruzi* displayed changes in the secretion of adipocytokines. There were decreased levels of adiponectin and leptin and increased levels of interleukin-6 and TNF-alpha [21]. Another study performed by Nagajyothi et al. showed increased expression of pro-inflammatory cytokines, including interleukin-6 and TNF-alpha in an adipocyte culture infected with *T. cruzi*. [22] Ferreira et al. recently observed persistence of *T. cruzi* in human adipocytes with chronic Chagas’ cardiomyopathy. However, the data are scarce in relation to adipocytokines levels in the chronic phase of CD in humans. [23]

In heart failure, regardless of the cause, adiponectin has a biphasic behavior, with reduced levels in diastolic HF and increased levels in systolic HF [24]. In our study, patients from IF

### Table 3. Evaluation of autonomic nervous system indices using the 24-hour Holter.

| Variable          | Control Group | IF Group   | ECG Group   | LVD Group     | p value * |
|-------------------|---------------|------------|-------------|---------------|-----------|
| Total power (ms²) | 2091.41 (1102.40) | 1181.28 (817.30)** | 1202.53 (1316.20) | 1178.97** (771.30) | 0.03      |
| LFr (ms²)         | 678.00 (524.70) | 422.30 (316.70) | 324.30 (442.00) | 284.90** (316.60) | 0.007     |
| HFr (ms²)         | 170.00 (161.50) | 63.50** (56.60) | 94.40 (153.10) | 58.80 (181.60) | 0.008     |
| LFr (n.u.)        | 75.60 (15.20)  | 86.20** (7.10)  | 81.60 (26.50)  | 75.00 (30.00) | 0.022     |
| HFr (n.u.)        | 24.30 (15.20)  | 13.70** (7.10)  | 18.30 (19.90)  | 24.90 (30.00) | 0.016     |
| LFr/HFr Ratio     | 3.10 (3.30)    | 6.20** (3.00)   | 4.40 (5.80)    | 3.00 (4.20)   | 0.028     |

Values expressed as medians (interquartile range)

* p values were calculated using Kruskal-Wallis test
** p <0.05 compared to control group using Tukey test

LFr: low frequency; HFr: high frequency; ms²: milliseconds squared; n.u.: normalized units.

doi:10.1371/journal.pone.0131447.t003

### Table 4. Evaluation of autonomic nervous system indices using the postural tilt test (supine position).

| Variable          | Control Group | IF Group   | ECG Group   | LVD Group     | p value * |
|-------------------|---------------|------------|-------------|---------------|-----------|
| Total power (ms²) | 2182.99 (1308.00) | 945.9 (1551.00) | 646.37** (589.02) | 1073.10 (2308.01) | 0.002     |
| LFr (ms²)         | 560.71 (364.42) | 264.61** (450.93) | 104.75** (68.47) | 178.46** (557.54) | 0.001     |
| HFr (ms²)         | 326.89 (178.71) | 73.64** (157.00) | 72.60** (280.00) | 362.60 (1005.11) | < 0.001   |
| LFr (n.u.)        | 68.74 (12.35)  | 70.78 (21.18)  | 63.19 (18.26)  | 27.68** (37.57) | 0.022     |
| HFr (n.u.)        | 31.01 (11.61)  | 29.21 (21.18)  | 36.80 (18.26)  | 72.31** (39.36) | 0.023     |
| LFr/HFr Ratio     | 2.19 (1.36)    | 2.42 (2.42)   | 1.71 (1.10)    | 0.38** (1.10)  | < 0.001   |

Values expressed as medians (interquartile range)

* p values were calculated using Kruskal-Wallis test
** p <0.05 compared to control group using Tukey test

LFr: low frequency; HFr: high frequency; ms²: milliseconds squared; n.u.: normalized units.

doi:10.1371/journal.pone.0131447.t004
group had no significant difference in adiponectin levels when compared with control group. This finding reinforces the good prognosis of IF form of Chagas’ disease, similar to general population [4]. We found higher levels of adiponectin in LVD and ECG groups, contrasting with the reduced levels found in the studies using animal models of acute infection [21]. The increase of adiponectin in the LVD group may be explained by the presence of systolic dysfunction and emphasizing that this group had less fat mass, which can also increase the levels of adiponectin.[25,26]

Table 5. Evaluation of autonomic nervous system indices using the postural tilt test (orthostatic position).

| Variable | Control Group | IF Group | ECG Group | LVD Group | p value * |
|----------|---------------|----------|-----------|-----------|-----------|
| Total power (ms²) | 1891.20 (1325.30) | 596.28** (558.82) | 613.36** (896.44) | 1001.77** (1122.88) | 0.005 |
| LFr (ms²) | 666.73 (1018.90) | 213.24** (262.26) | 260.53** (356.76) | 84.65** (394.67) | 0.009 |
| HFr (ms²) | 154.75 (157.22) | 39.18** (77.01) | 98.02 (94.55) | 329.95 (612.96) | < 0.001 |
| LFr (n.u.) | 83.21 (14.21) | 82.37 (11.50) | 77.80 (28.16) | 35.97** (42.26) | 0.007 |
| HFr (n.u.) | 16.78 (14.21) | 17.62 (11.50) | 22.19 (28.16) | 64.02** (42.26) | 0.006 |
| LFr/HFr Ratio | 4.95 (4.13) | 4.67 (5.72) | 3.50 (2.89) | 0.56** (1.34) | 0.019 |
| Change LFr (n.u.) | 21.58 (23.04) | 14.14 (25.34) | 8.26 (16.33) | 4.93 (51.83)** | 0.02 |
| Change HFr (n.u.) | -37.11 (33.97) | -42.96 (46.60) | -25.80 (25.63) | -9.85 (18.18)** | < 0.001 |

Values expressed as medians (interquartile range)
* p values were calculated using Kruskal-Wallis test
** p <0.05 compared to control group using Tukey test

LFr: low frequency; HFr: high frequency; ms²: milliseconds squared; n.u.: normalized units.; Change LFr and HFr (n.u.): Change of each component from rest to orthostatic position in normalized units

doi:10.1371/journal.pone.0131447.t005

Table 6. Spearman rank correlation coefficients of adiponectin with autonomic nervous system indices and inflammatory cytokines.

| Variable | IF group | ECG group | LVD group |
|----------|----------|-----------|-----------|
| LFr (n.u.) in 24-hour Holter | 0.114 (p = 0.685) | -0.539 (p = 0.038)* | -0.075 (p = 0.791) |
| HFr (n.u.) in 24-hour Holter | 0.079 (p = 0.781) | 0.539 (p = 0.038)* | 0.075 (p = 0.791) |
| LFr/HFr Ratio in 24-hour Holter | -0.114 (p = 0.685) | -0.518 (p = 0.048)* | -0.075 (p = 0.791) |
| LFr (n.u.) in postural tilt test (supine position) | 0.318 (p = 0.248) | -0.275 (p = 0.321) | 0.339 (p = 0.216) |
| HFr (n.u.) in postural tilt test (supine position) | -0.318 (p = 0.248) | 0.275 (p = 0.321) | -0.364 (p = 0.182) |
| LFr/HFr Ratio in postural tilt test (supine position) | 0.318 (p = 0.248) | -0.293 (p = 0.289) | 0.364 (p = 0.182) |
| LFr (n.u.) in postural tilt test (orthostatic position) | 0.100 (p = 0.723) | 0.054 (p = 0.850) | 0.300 (p = 0.277) |
| HFr (n.u.) in postural tilt test (orthostatic position) | -0.100 (p = 0.723) | -0.054 (p = 0.850) | -0.300 (p = 0.277) |
| LFr/HFr Ratio in postural tilt test (orthostatic position) | 0.100 (p = 0.723) | 0.054 (p = 0.850) | 0.304 (p = 0.271) |
| Interleukin-6 | -0.061 (p = 0.830) | -0.496 (p = 0.329) | -0.003 (p = 0.934) |
| TNF-alpha | 0.383 (p = 0.349) | -0.500 (p = 0.667) | 0.429 (p = 0.397) |

* P value < 0.05

HFr: high frequency; LFr: low frequency; n.u.: normalized units; TNF-alpha: Tumor Necrosis Factor-alpha

There were significant correlations between leptin with some ANS assessment indexes in LVD group. Leptin level is associated positively with the LFr component and negatively with the HFr component in 24-hour Holter. No correlations between leptin and inflammatory cytokines were found. The values of correlations of leptin are shown in Table 7.

doi:10.1371/journal.pone.0131447.t006
authors observed a moderate rate of progression to cardiomyopathy with systolic dysfunction and HF in patients with ECG abnormalities (1.85% per year) [27].

Although the electrocardiogram is an established marker of severity of Chagas’ disease, the increased adiponectin levels found in patients with ECG abnormalities without systolic dysfunction suggest that adiponectin may help to identify patients at higher risk of developing systolic HF in this group.

It is not well established where adiponectin is predominantly secreted in HF patients and if its increased levels are only a compensation mechanism. Adiponectin is synthetized almost exclusively by adipocytes and its expression seems to be regulated by distinct signaling pathways [12]. Some studies suggest that adiponectin is over expressed in adipocytes from adipose tissue of systolic HF patients [28,29]. Additionally, other studies indicate the presence of a cardiac adiponectin system with independent regulation and with dysfunction in HF. Adiponectin is released from the cardiomyocytes into the peripheral circulation in proportion to extent of systolic dysfunction irrespective of etiologies of HF [30,31]. Moreover, Nagajyothi et al. has shown that adiponectin is considerably produced in the heart during Chagas’ acute infection. However, it is not well established the mechanism by which this occurs and the significance of elevated adiponectin levels in the heart during acute and chronic Chagas’ infection [32].

Many mechanisms have been proposed for the increase of adiponectin in systolic HF of any cause. The patients with cardiac cachexia showed higher adiponectin levels than the patients with systolic HF without cachexia. It is still not clear if the increased adiponectin levels in these patients are a cause or effect of cachexia [25,26]. Bobbert et al. demonstrated that patients with inflammatory cardiomyopathy have higher levels of adiponectin than patients with non-inflammatory cardiomyopathy and that, between the patients with inflammatory cardiomyopathy, those that have higher levels of adiponectin had better outcomes. These data suggest that the increase of adiponectin could act as a compensation mechanism due its anti-inflammatory action [33]. Other mechanisms proposed for the increase of adiponectin in systolic HF are a compensatory effect for the resistance to insulin found in HF or a mechanism of resistance to the action of adiponectin [34].

However, among the variables assessed in our study, the increased levels of adiponectin was associated with ANS function in patients with early phase of Chagas’ heart disease. There was a negative association with the sympathetic branch and a positive association with the

| Variable | IF group | ECG group | LVD group |
|----------|----------|-----------|-----------|
| LfFr (n.u.) in 24-hour Holter | 0.396 (p = 0.143) | -0.182 (p = 0.869) | 0.632 (p = 0.011)* |
| HfFr (n.u.) in 24-hour Holter | -0.414 (p = 0.125) | -0.046 (p = 0.516) | -0.632 (p = 0.011)* |
| LFr/HFr Ratio in 24-hour Holter | 0.414 (p = 0.125) | -0.034 (p = 0.904) | 0.632 (p = 0.011)* |
| LFr (n.u.) in postural tilt test (supine position) | -0.236 (p = 0.398) | 0.404 (p = 0.136) | 0.329 (p = 0.232) |
| HFr (n.u.) in postural tilt test (supine position) | 0.236 (p = 0.398) | -0.404 (p = 0.136) | -0.361 (p = 0.187) |
| LFr/HFr Ratio in postural tilt test (supine position) | -0.236 (p = 0.398) | 0.400 (p = 0.140) | 0.361 (p = 0.187) |
| LFr (n.u.) in postural tilt test (orthostatic position) | 0.068 (p = 0.810) | 0.200 (p = 0.475) | 0.168 (p = 0.550) |
| HFr (n.u.) in postural tilt test (orthostatic position) | -0.068 (p = 0.810) | -0.200 (p = 0.475) | -0.168 (p = 0.550) |
| LFr/HFr Ratio in postural tilt test (orthostatic position) | 0.068 (p = 0.810) | 0.200 (p = 0.475) | 0.154 (p = 0.584) |
| Interleukin-6 | 0.118 (p = 0.676) | -0.371 (p = 0.468) | -0.214 (p = 0.467) |
| TNF-alpha | 0.395 (p = 0.333) | -0.500 (p = 0.667) | -0.261 (p = 0.111) |

* P value < 0.05

HFr: high frequency; LFr: low frequency; n.u.: normalized units; TNF-alpha: Tumor Necrosis Factor-alpha

doi:10.1371/journal.pone.0131447.t007
parasympathetic branch of ANS in ECG group. Our study does not allow conclusions on casual inference or the effect of one variable over the other. However, previous publications described possible pathways for this association.

Other studies, in different models, demonstrate the same inverse association between adiponectin and sympathetic activity found in our study. Studies in animals and humans, with cold exposure as a way to activate the sympathetic nervous system, showed reduced levels of adiponectin [35,36]. An association has also been reported between hypoadiponectinemia and sympathetic hyperactivity in patients with diabetes mellitus and obstructive sleep apnea [37–40]. This interaction between adiponectin and the sympathetic nervous system seems to be in a two-way. A study carried out by Tanida et al. showed that the intravenous infusion of adiponectin reduced renal sympathetic nerve activity in animal models [41]. On the other hand, in vitro and in vivo studies conducted using beta-adrenergic agonists have shown decreased expression and secretion of adiponectin through a direct inhibitory effect on the adipocytes [42,43].

Adipose tissue is predominantly innervated by the sympathetic nervous system [44,45]. In our study, we can speculate that the peripheral impairment of the sympathetic nervous system in chagasic patients could lead to a reduction in sympathetic activity in the adipose tissue and increase the secretion of adiponectin. This mechanism can be explained in two ways. The first mechanism is that the impairment of the sympathetic system could lead to the direct loss of the inhibitory effect of the adrenergic tone on the expression and secretion of adiponectin by the adipocytes [42,43]. On the other hand, the main action of the sympathetic nervous system on the adipose tissue is to stimulate lipolysis with increased production of free fatty acids [44,45]. The accumulation of free fatty acids in the adipose tissue reduces the secretion of adiponectin [46,47]. Therefore, the reduction of sympathetic activity in the adipose tissue could reduce lipolysis and reduce the production of free fatty acids, leading to increased levels of adiponectin.

With regard to others metabolic parameters, insulin, in the majority of studies, demonstrate a reduction of its levels or a compromise of its function in Chagas’ disease patients [48–50]. The data on leptin levels from previous studies vary in heart failure patients. Some studies have shown raised levels, especially in more advanced functional classes [17,51], and other studies have demonstrated reduced levels, particularly in patients with cachexia [18,52]. In patients with Chagas’ disease, we have previously found reduced levels in patients with HF when compared with a control group and other forms of CD [19]. In the present study, we did not detect significant differences in the levels of insulin and leptin between the different groups.

However, we observed a positive association between leptin levels and sympathetic activity in LVD group. Leptin’s relationship with the sympathetic component of the ANS is two-way, with increased secretion of leptin leading to increased sympathetic activity, and sympathetic activity inhibiting the synthesis of leptin [53,54]. Paolisso et al. described, in healthy subjects, the same positive association between leptin levels and sympathetic activity found in our study [55]. Other studies demonstrated that acute and chronic increase in plasma leptin levels triggers a remarkable increase in sympathetic activity in various organs including the adipose tissue [56,57].

With regard to associations observed in our study, we have to address that the small sample size, although homogeneous, may have reduced the power to detect other associations.

Our findings in ANS study were also observed in others publications. Autonomic involvement is a well-established feature of CD, in which anatomic and functional abnormalities have been extensively described. The majority of studies observed parasympathetic dysautonomia preceding left ventricular systolic dysfunction and a progressive involvement of sympathetic system in advanced Chagas’ heart disease [7,8,58].
In our study, we observed HFr indexes in LVD group equivalent or higher when compared with control group. We did not interpret these findings as a normal vagal function in patients with systolic dysfunction. The reciprocal relationship or push-pull organization of LFr and HFr components of HRV, which can be better appreciated by using a normalization procedure, shows a view of a predominance of an ANS branch over the other, named as sympatho-vagal balance [20]. So, our study suggests that there was a greater impairment of sympathetic system and a predominance of parasympathetic activity in LVD group, although there was involvement of both. Another reason for this finding is that, for ethical reasons, we chose not to suspend the use of prescribed medications. So all patients in the LVD group were using beta-blockers, which can increase cardiac vagal modulation and lower sympathetic activity, increasing HFr indexes [59].

Another issue to be discussed is the controversy about the use of LFr component as a marker of sympathetic modulation. Some authors consider that this component is a parameter that includes both sympathetic, vagal and baroreflex influences, especially in rest [60]. We used the concept of the international Task Force document of Heart Rate Variability which considers LFr component (especially when expressing it in normalized units) as an index of sympathetic modulation [20].

**Conclusions**

In conclusion, we found increased adiponectin levels in Chagas’ heart disease with and without significant systolic dysfunction. Furthermore, adipocytokines levels were associated with some ANS parameters. Adiponectin levels were positively associated with HFr component and inversely associated with LFr component in ECG group and leptin levels were inversely associated with HFr component and positively associated with LFr component of HRV in LVD group.

This is the first study to investigate the influence of cardiac autonomic function, as estimated by HRV, on serum adipocytokines in chagasic patients. We used Chagas’ disease as a model in which autonomic dysfunction influences adipocytokine levels, which are important metabolic parameters in cardiovascular function. A better understanding of the relationship between autonomic and adipose tissue functions can lead to further evaluation for determining which individuals are at the highest risk for cardiovascular disease and mortality, and can also lead to the development of new therapies for reducing that risk.

**Author Contributions**

Conceived and designed the experiments: JMB FF HFL BMI FJAR CM. Performed the experiments: JMB FF VMCS CJG DTH. Analyzed the data: JMB FF HFL BMI FJAR. Contributed reagents/materials/analysis tools: JMB FF VMCS CJG DTH. Wrote the paper: JMB FF HFL FJAR CM.

**References**

1. World Health Organization (2012) Research priorities for Chagas Disease, Human African Trypanosomiasis and Leishmaniasis: Technical Report of the TDR Disease Reference Group on Chagas Disease, Human African Trypanosomiasis and Leishmaniasis. Geneva, Switzerland: WHO.
2. Gascon J, Berr C, Pinazo MJ (2010) Chagas disease in Spain, the United States and other non-endemic countries. Acta Tropica 115:22–7. doi:10.1016/j.actatropica.2009.07.019 PMID: 19646412
3. Prata A (2001) Clinical and epidemiological aspects of Chagas' disease. Lancet Infect Dis 1:92–100. PMID: 11871482
4. Ianni BM, Arteaga E, Frim CC, Barretto ACO, Mady C (2001) Chagas' heart disease: Evolutive evaluation of eletrocardiographic and echocardiographic parameters in patients with the indeterminate form. Arq Bras Cardiol 77:59–62. PMID: 11500748

5. Marin-Neto JA, Cunha-Neto E, Maciel BC, Simões MV (2007) Pathogenesis of chronic Chagas Heart Disease. Circulation 115:1109–23. PMID: 17339569

6. Dávila DF, Inglessis G, Dávila CAM (1998) Chagas' heart disease and the autonomic nervous system. Int J Cardiol 66:123–127. PMID: 9829322

7. Ribeiro ALP, Moraes RS, Ribeiro JP, Ferlin EL, Torres RM, Oliveira EO et al. (2001) Parasympathetic dysautonomia precedes left ventricular systolic dysfunction in Chagas disease. Am Heart J 141:260–5. PMID: 11174350

8. Molina RBB, Matsubara BB, Hueb JC, Zanati SG, Meira DA, Cassolato JL et al. (2006) Dysautonmia and ventricular dysfunction in the indeterminate form of Chagas disease. Int J Cardiol 113:188–93. PMID: 16376440

9. Doehner W, Frenneaux M, Anker SD (2014) Metabolic impairment in heart failure: the myocardial and systemic perspective. J Am Coll Cardiol 64:1388–1400. doi: 10.1016/j.jacc.2014.04.083 PMID: 25257642

10. Lopes HF, Egam BM (2006) Autonomic dysregulation and the metabolic syndrome: Pathologic partners in an emerging global pandemic. 87:538–47. PMID: 17128327

11. Wojchemberg BL, Nery M, Cunha MR, Silva MER (2009) Adipose tissue at the crossroads in the development of the metabolic syndrome, inflammation and atherosclerosis. Arq Bras Endocrinol Metab 53:145–50.

12. Antoniades C, Antonopoulos AS, Tousoulis D, Stefanadis C (2009) Adiponectin: from obesity to cardiovascular disease. Obesity Reviews 10:269–79. doi: 10.1111/j.1467-789X.2009.00571.x PMID: 19389061

13. Guzik TJ, Mangalat D, Korbut R (2006) Adipocytokines- Novel link between inflammation and vascular function? J Physiol and Pharmacol 57:505–28.

14. Berg AH, Scherer PE (2005) Adipose tissue, inflammation and cardiovascular disease. Circulation Res 96:939–49. PMID: 15890981

15. George J, Patal S, Wexler D, Sharabi Y, Pelg E, Kamari Y et al. (2006) Circulating adiponectin concentrations in patients with congestive heart failure. Heart 92:1420–4. PMID: 16621874

16. Dieplinger B, Gegenhuber A, Poelz W, Haltmayer M, Mueller T (2009) Prognostic value of increased adiponectin plasma concentrations in patients with acute destabilized heart failure. Clin Biochem 42:1190–3. doi: 10.1016/j.clinbiochem.2009.02.023 PMID: 19272369

17. Schulze PC, Kratzch J, Linke A, Schoene N, Adams V, Gielen S et al (2003) Elevated serum levels of leptin and soluble leptin receptor in patients with chronic heart failure. Eur J Heart Fail 5:33–40. PMID: 12559213

18. Filippatos GS, Tsilias K, Venetsanou K, Karambinos E, Manolatos D, Kranidis A et al. (2000) Leptin serum levels in cachetic heart failure patients. Relationship with tumor necrosis factor-alpha system. Int J Cardiol 76:117–22. PMID: 11104865

19. Fernandes F, Dantas S, Ianni BM, Ramires FJA, Buck P, Salemi VMC et al. (2007) Leptin levels in different forms of Chagas' disease. Braz J Med Biol Res 40:1631–6. PMID: 17713658

20. European Society of Cardiology (1996) Task force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Heart rate variability: standards of measurement, physiological, interpretation and clinical use. Circulation 93:1043–65. PMID: 8598068

21. Coombs TP, Mukherjee Salmeida CJG, Jelicks LA, Schubert W, Lin Y, Jayabalans DS et al (2005) The adipocyte as an important target cell for infection with Trypanosoma cruzi. J Biol Chem 280:24085–94. PMID: 15943370

22. Nagajothy F, Desruisseaux MS, Thiruvur N, Weiss LM, Braunstein VL, Albanese C et al. (2008) Trypanosoma cruzi infection of cultured adipocytes results in an inflammatory phenotype. Obesity 16: 1938–2008. PMID: 18398074

23. Ferreira AVM, Segatto M, Menezes Z, Macedo AM, Gelape C, Andrade LO et al. (2011) Evidence for Trypanosoma cruzi in adipose tissue in human chronic Chagas disease. Microbes Infect 13:1002–5. doi: 10.1016/j.micinf.2011.06.002 PMID: 21726660

24. Fu M, Zhou J, Qian J, Jin X, Zhu H, Zhong C et al. (2012) Adiponectin through its biphasic serum is a useful biomarker during transition from diastolic dysfunction to systolic dysfunction- an experimental study. Lipids Health Dis 11:106–15. doi: 10.1186/1476-511X-11-106 PMID: 22935137

25. McEntegart MB, Awede B, Petrie MC, Sattar N, Dunn FG, Macfarlane NG et al.(2007) Increase in serum adiponectin concentration in patients with heart failure and cachexia: relationship with leptin, other cytokines, and B-type natriuretic peptide. Eur Heart J 28:829–35. PMID: 17403719
26. Araújo JP, Lourenço P, Rocha-Gonçalves F, Ferreira A, Bettencourt P (2009) Adiponectin is increased in cardiac cachexia irrespective of body mass index. Eur J Heart Fail 11:567–72. doi: 10.1093/eurheartj/ hp046 PMID: 19359328

27. Sabino EC, Ribeiro AL, Salemi VM, Di Lorenzo Oliveira C, Antunes AP, Menezes MM et al. (2013) Ten years incidence of Chagas cardiomyopathy among asymptomatic Trypanosoma cruzi-seropositive former blood donors. Circulation 127:1105–15. doi: 10.1161/CIRCULATIONAHA.112.123612 PMID: 23393012

28. Tsukamoto O, Fujita M, Kato M, Yamazaki S, Asano Y, Ogai A et al. (2009) Natriuretic peptides enhance the production of adiponectin in human adipocytes and in patients with chronic heart failure. J Am Coll Cardiol 53:2070–7. doi: 10.1016/j.jacc.2009.02.038 PMID: 19477358

29. Khan RS, Kato TS, Chokshi A, Chew M, Yu S, Wu C et al. (2012) Adipose tissue inflammation and adiponectin resistance in patients with advanced heart failure: Correction after ventricular assist device implantation. Circ Heart Fail 5:340–8. doi: 10.1161/CIRCHEARTFAILURE.111.964031 PMID: 22379072

30. Skurk C, Wittchen F, Suckau L, Witt H, Noutsias M, Fechner H et al. (2008) Description of a local cardiac adiponectin system and its deregulation in dilated cardiomyopathy. Eur Heart J 29:1168–80. doi: 10.1093/eurheartj/ehn136 PMID: 18390538

31. Takano H, Obata J, Kodama Y, Kitta Y, Nakamura T, Mende A et al. (2009) Adiponectin is released from the heart in patients with heart failure. Int J Cardiol 132:221–6. doi: 10.1016/j.ijcard.2007.11.040 PMID: 18192035

32. Nagajhioti F, Weiss LM, Zhao D, Jelicks LA, Cui M et al. (2014) High fat diet modulates adiponectin expression during gestation and lactation. J Matern Fetal Neonatal Med 27:1526–30. doi: 10.3109/14767058.2013.777545 PMID: 23738507

33. Bobbert P, Scheibenbogen C, Jenke A, Kania G, Wilk S, Krohn S et al. (2011) Adiponectin expression is decreased in patients with heart failure. Circ Cardiovasc Imaging 4:46–51. doi: 10.1161/CIRCIMAGING.110.951576 PMID: 21518123

34. Fasshauer M, Klein J, Neumann S, Eszlinger M, Paschchke R (2001) Adiponectin gene expression is inhibited by ß-adrenergic stimulation via protein kinase A in 3T3-L1 adipocytes. FEBS Lett 507:142–5. doi: 10.1016/S0014-5793(01)02466-2 PMID: 11357980

35. Imai J, Katagiri H, Yamada T, Ishigaki Y, Ogihara T, Uno K et al. (2006) Cold exposure suppresses the sympathetic nervous system activity and blood pressure in rats. Exp Biol Med 232:390–7. doi: 10.1165/creator/Adipocytokines Levels in Chagas' Heart Disease

37. Wakabayashi S, Aso Y (2004) Adiponectin concentrations in sera from patients with type 2 diabetes are negatively associated with sympathovagal balance as evaluated by power spectral analysis of heart rate variation. Diabetes Care 27:2392–7. PMID: 15451906

38. Takahashi N, Anan F, Nakagawa M, Yufu K, Shinohara T, Tsubone T et al. (2007) Hypoadiponectinemia in type 2 diabetes mellitus in men is associated with overactivity as evaluated by cardiac 123I-metaiodobenzylguanidine scintigraphy. Metabolism 56:919–24. PMID: 17570253

39. Lieb DC, Parson HK, Mamikunian G, Vinik AI (2012) Cardiac autonomic imbalance in newly diagnosed and established diabetes is associated with markers of adipose tissue inflammation. Exp Diabetes Res 2012:1–7.

40. Lam JC, Xu A, Tam S, Khong PI, Yao TJ, Lam DC et al. (2008) Hypoadiponectinemia is related to sympathetic activation and severity of obstructive sleep apnea. Sleep 31:1721–7. PMID: 19090328

41. Tanida MT, Shen J, Horii Y, Matsuoka M, Kihara S, Funahashi T et al. (2007) Effects of adiponectin on the renal sympathetic nerve activity and blood pressure in rats. Exp Biol Med 232:390–7.

42. Fasshauer M, Klein J, Neumann S, Eszlinger M, Paschchke R (2001) Adiponectin gene expression is inhibited by β-adrenergic stimulation via protein kinase A in 3T3-L1 adipocytes. FEBS 507:142–5.

43. Delporte ML, Funahashi T, Takahashi M, Matsuura Y, Brichard SM (2002) Pre- and post-translational negative effect of β-adrenergic receptor agonists on adiponectin secretion: in vitro and in vivo studies. Biochem J 367:677–85. PMID: 12139486

44. Bartness TJ, Song CK (2007) Sympathetic and sensory innervation of white adipose tissue. J Lipid Res 48:1655–72. PMID: 17460327

45. Bartness TJ, Shrestha YB, Vaughan CH, Schwartz GJ, Song CK (2010) Sensory and sympathetic nerve system control of white adipose tissue. Mol Cell Endocrinol 318–343.

46. Karki S, Chakraborti P, Huang G, Huang H, Farmer SR, Kundor KV (2011) The multi-level action of fatty acids on adiponectin production by fat cells. PLoS One 6:e28146. doi: 10.1371/journal.pone.0028146 PMID: 22140527
47. Moro C, Klimcakova E, Loimede K, Berlan M, Lafontan M, Stich V et al. (2007) Atrial natriuretic peptides inhibits the production of adipokines and cytokines linked to inflammation and insulin resistance in human subcutaneous adipose tissue. Diabetologia 50:1038–47. PMID:17318625

48. Oliveira LCM, Juliano Y, Novo NF, Neves MM (1993) Blood glucose and insulin response to intravenous glucose by patients with chronic Chagas’ Disease and alcoholism. Braz J Med Biol Res 26:1187–90. PMID:8136719

49. Guariento ME, Saad MJA, Muscelli EOA, Gontijo JAR (1993) Heterogeneous insulin response to an oral glucose load by patients with indeterminate clinical form of Chagas’ disease. Braz J Med Biol Res 26:491–5. PMID:8257938

50. Nagajyothi F, Kuliawat R, Kusminski CM, Machado FS, Desruisseaux MS, Zhao D et al. (2013) Alterations in glucose homeostasis in a murine model of Chagas disease. Am J Pathol 182:886–94. doi: 10.1016/j.ajpath.2012.11.027 PMID: 23321322

51. Schulze PC, Biolo A, Gopal D, Shahzad K, Balog J, Fish M et al. (2011) Dynamics in insulin resistance and plasma levels of adipokines in patients with acute decompensated and chronic stable heart failure. J Cardiac Fail 17:1004–11.

52. Murdoch DR, Rooney E, Dargie HJ, Shapiro D, Morton JJ, McMurray JJV (1999) Inappropriately low plasma leptin concentration in the cachexia associated with chronic heart failure. Heart 82:352–6. PMID: 10455089

53. Barbosa-Ferreira JM, Fernandes F, Dabarian A, Mady C (2013) Leptin in heart failure. Expert Opin Med Diagn 7:113–7. doi: 10.1517/17530059.2013.735229 PMID: 23530847

54. Trayburn P, Duncan JS, Hoggard N, Rayner DV (1998) Regulation of leptin production: a dominant role for the sympathetic nervous system?. Proc Nutr Soc 57:413–9 PMID: 9793999

55. Paolisso G, Manzella D, Montano N, Gambardella A, Varricchio M (2000) Plasma Leptin concentrations and cardiac autonomic nervous system in healthy subjects with different body weights. J Clin Endocrinol Metab 85:1810–4. PMID: 10843157

56. Grassi G, Elam M (2002) Leptin, sympathetic and baroreflex function: another step on the road to sympathetic differentiation. J Hypertens 20:1487–9. PMID: 12172307

57. Hausberg M, Morgan DA, Chapleau MA, Sivitz WI, Mark AL, Haynes WG (2002) Differential modulation of leptin-induced sympathoexcitation by baroreflex activation. J Hypertens 20:1633–41. PMID: 12172326

58. Simões MV, Pintya AO, Bromberg-Marin G, Sarabanda AV, Antloga CM, Pazin-Filho A et al. (2000) Relation of regional sympathetic denervation and myocardial perfusion disturbance to wall motion impairment in Chagas’ cardiomyopathy. Am J Cardiol 86:975–981. PMID: 11053710

59. Bloom HL, Vinik AI, Colombo J (2014) Differential effects of adrenergic antagonists (carvedilol vs metoprolol) on parasympathetic and sympathetic activity: a comparison of clinical results. Heart Int 9:15–21.

60. Goldstein DS, Benthal O, Park M, Sharabi Y (2011) LF power of heart rate variability is not a measure of cardiac sympathetic but may be a measure of modulations of cardiac autonomic outflows by baroreflexes Exp Phisiol 96:1255–61.